Updates are available Correction dated 2023-08-31
Click to view Correction: https://doi.org/10.1038/s43588-023-00523-1
-
Authors
Chen, Xi
Wang, Yuan http://orcid.org/0000-0001-7750-3587
Cappuccio, Antonio
Cheng, Wan-Sze
Zamojski, Frederique Ruf http://orcid.org/0000-0002-2451-8598
Nair, Venugopalan D.
Miller, Clare M.
Rubenstein, Aliza B.
Nudelman, German
Tadych, Alicja
Theesfeld, Chandra L. http://orcid.org/0000-0002-8379-6600
Vornholt, Alexandria
George, Mary-Catherine
Ruffin, Felicia
Dagher, Michael
Chawla, Daniel G.
Soares-Schanoski, Alessandra
Spurbeck, Rachel R.
Ndhlovu, Lishomwa C.
Sebra, Robert
Kleinstein, Steven H. http://orcid.org/0000-0003-4957-1544
Letizia, Andrew G. http://orcid.org/0000-0002-7361-5917
Ramos, Irene http://orcid.org/0000-0002-0223-0120
Fowler, Vance G. Jr
Woods, Christopher W.
Zaslavsky, Elena http://orcid.org/0000-0002-4828-7771
Troyanskaya, Olga G.
Sealfon, Stuart C. http://orcid.org/0000-0001-5791-1217
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 6 June 2023
First Online: 25 July 2023
Change Date: 31 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43588-023-00523-1
Competing interests
: A.G.L. is a military service member. This work was prepared as part of his official duties. Title 17, US Code §105 provides that copyright protection under this title is not available for any work of the US Government. Title 17, US code §101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties. The views expressed in the article are those of the authors and do not necessarily express the official policy and position of the US Navy, the Department of Defense, the US Government, or the institutions affiliated with the authors. V.G.F. reports personal fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, Deep Blue, Basilea, Janssen; Royalties from UpToDate, stock options from Valanbio and ArcBio, Honoraria from Infectious Diseases of America for his service as Associate Editor of Clinical Infectious Diseases, and a patent sepsis diagnostics pending. L.C.N. has received consulting fees from work as a scientific advisor for AbbVie, ViiV Healthcare, and Cytodyn and also serves on the Board of Directors of CytoDyn and has financial interests in Ledidi AS, all for work outside of the submitted work. S.C.S. is a founder of GNOMX Corp and serves as chief scientific officer. The remaining authors declare no competing interests.
